Srs Capital Advisors, Inc. Supernus Pharmaceuticals, Inc. Transaction History
Srs Capital Advisors, Inc.
- $1.48 Billion
- Q1 2025
A detailed history of Srs Capital Advisors, Inc. transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Srs Capital Advisors, Inc. holds 42 shares of SUPN stock, worth $1,369. This represents 0.0% of its overall portfolio holdings.
Number of Shares
42
Previous 122
65.57%
Holding current value
$1,369
Previous $4,000
75.0%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding SUPN
# of Institutions
305Shares Held
60.8MCall Options Held
8.8KPut Options Held
6.3K-
Black Rock Inc. New York, NY10.4MShares$339 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.16MShares$201 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY5.2MShares$169 Million2.59% of portfolio
-
Dimensional Fund Advisors LP Austin, TX2.9MShares$94.7 Million0.02% of portfolio
-
Macquarie Group LTD Australia, C32.7MShares$88 Million0.11% of portfolio
About SUPERNUS PHARMACEUTICALS, INC.
- Ticker SUPN
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 53,495,300
- Market Cap $1.74B
- Description
- Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...